Journal of Clinical Oncology
Articles in this Issue
Real-world outcomes of polatuzumab, rituximab, and lenalidomide in frail pts with diffuse large B-cell lymphoma.
e19055 Background: Patients (pts) with diffuse large B-cell lymphoma (DLBCL) who are elderly, frail, or have cardiac comor...
Standardizing communication during ICU transfers of oncology patients.
e23299 Background: Oncology patients have complex care plans. During transitions of care, precise communication of diagnos...
TGF-β signaling alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–enabled precision oncology study in diverse populations.
3649 Background: The transforming growth factor–β (TGF-β) signaling pathway plays a complex, context-dependent role in col...
Operative and non-operative management of small bowel obstruction in colorectal cancer hospitalizations: A national inpatient sample analysis.
e15630 Background: Small Bowel Obstruction (SBO) is a common and serious complication among patients with Colorectal cance...
Antigen-switch and BCR-axis–enriched multi-target CAR T re-infusion after prior CAR T failure in R/R B-cell NHL.
e19017 Background: Relapse after CAR T-cell therapy remains a critical unmet need in relapsed/refractory (R/R) B-cell non-...
Health-related quality of life following tumor-infiltrating lymphocyte (TIL) therapy with commercial lifileucel in metastatic melanoma: Real-world longitudinal patient-reported outcomes.
9547 Background: Although the efficacy of lifileucel has been demonstrated in metastatic melanoma, real-world longitudinal...
Safety and efficacy of B7H3/IL13Rα2 bispecific armored CAR-T for treatment of recurrent/refractory glioblastoma.
e14062 Background: Recurrent/refractory glioblastoma (GBM) carries an extremely poor prognosis with limited therapeutic op...
Experiences of a cancer survivorship elective in a US medical school: The first 10 years.
9025 Background: Cancer survivorship care is an increasingly important competency in medical education, but early introduc...
An exploratory study of the potential clinical impact of ethnicity in patients with retroperitoneal sarcoma.
e23533 Background: Surgery is the mainstay of treatment for localized retroperitoneal sarcoma (RPS), but emerging data and...
Effect of nanobody-STING agonists on the tumor microenvironment and adoptive cell therapy for solid tumors.
e14601 Background: Adoptive cell therapies (ACT), including TCR- and CAR-engineered T cells, have demonstrated durable cli...
Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve biomarker testing in early-stage NSCLC.
8044 Background: Non-adherence to guideline-concordant biomarker testing in non-small cell lung cancer (NSCLC) can limit a...
Phase 2 study of metronomic cyclophosphamide with pembrolizumab in checkpoint inhibitor–refractory melanoma.
TPS9599 Background: Immune checkpoint inhibitors (ICI) are standard of care treatment in advanced, metastatic melanoma as...
Doctor, am I cured? Characteristics of long-term survivors with advanced melanoma treated with immunotherapy.
e21502 Background: Immune checkpoint inhibitors (ICIs) have transformed the prognosis of advanced melanoma, enabling a sub...
Obesity-associated genomic heterogeneity in breast tumors.
e12611 Background: Obesity is associated with increased breast cancer risk and worse outcomes; however, its molecular and...
A feasibility study of tumor-infiltrating lymphocytes (TIL) in patients with cutaneous squamous cell carcinoma and Merkel cell carcinoma after anti–PD-1 therapy.
TPS9616 Background: Tumor infiltrating lymphocyte (TIL) therapy is an autologous cellular therapy isolated from a patient'...
Overcoming resistance to prior CAR-T therapy: Efficacy and safety of a sequential, multi-antigen targeted CAR T-cell strategy in B-cell NHL.
7021 Background: Relapse following CAR T-cell therapy is a significant unmet need for patients with B-cell non-Hodgkin lym...
DNA methylation–based liquid biopsy for longitudinal monitoring of treatment response in metastatic breast cancer.
e15051 Background: Treatment response in metastatic breast cancer patients is currently monitored with CT-scans every 3-6...
Use of a patient-facing digital tool for glioblastoma outside scheduled clinic visits.
1514 Background: Care for patients with glioblastoma is largely organized around scheduled clinic encounters, yet symptom...
Phase III CR-SEQUENCE trial of FOLFOX+panitumumab followed by FOLFIRI+bevacizumab (SEQ1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (SEQ2) in previously untreated RAS wild-type, left-sided, unresectable metastatic colorectal cancer.
3512 Background: The optimal sequencing of systemic therapy for patients with RAS wild-type, left-sided metastatic colorec...
Effect of statin use on survival in patients with endometrial cancer.
e17641 Background: Statin use has been found to reduce cancer related mortality in multiple cancer types. Prior studies ha...
Comparative efficacy of immune checkpoint inhibitor backbones in <i>STK11/KEAP1</i> -mutant advanced non–small cell lung cancer: A systematic review and meta-analysis.
e20640 Background: Immunotherapy is a cornerstone of treatment for advanced non–small cell lung cancer (NSCLC), though eff...
Sociodemographic variation in live birth incidence and access to assisted reproductive services among female cancer patients in the United States.
1640 Background: Sociodemographic variation in fertility outcomes after cancer is not well described. We constructed a nov...
The long-term influence of adverse social determinants of health on clinical outcomes in breast cancer survivors: Insights from a propensity score–matched cohort study using federated electronic health records.
e12745 Background: Social determinants of health (SDOH), including housing instability, food insecurity, and socioeconomic...
Rad2Nivo: Phase IB study of radium-223 (Rad) with nivolumab (Nivo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
5060 Background: Rad is an α-emitting calcium-mimetic radiopharmaceutical that is FDA approved for pts with mCRPC with sym...
A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of HPV-negative, PD-L1–positive, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): FORTIFI-HN01.
TPS6129 Background: HPV-negative HNSCC is an aggressive disease characterized by high rates of recurrence, metastasis, and...